Primary Sjogren's syndrome: Pathophysiological, clinical and therapeutic advances
Primary Sjogren's syndrome: Pathophysiological, clinical and therapeutic advances
复制标题
DOI：
10.1016/j.jbspin.2009.09.006
复制
发表时间：
2009-12-01
期刊：
影响因子：
4.2
通讯作者：
Gottenberg, J. -E.
中科院分区：
文献类型：
--
作者：
Gottenberg, J. -E.
原发性干燥综合征长期以来一直是一个令人烦恼的困境，因为潜在的病理生理机制仍然不清楚，疾病活动性难以评估，并且没有已知有效的特定治疗方法。然而，近年来这三个领域取得了重大进展。已获得令人信服的证据表明先天免疫（尤其是由干扰素介导）在 B 细胞的初始激活中发挥作用。疾病活动评分是在 EULAR 主办的共识会议上制定的。更重要的是，B 细胞耗竭是一种非常有前途的治疗方法。因此，利妥昔单抗在两项对照临床试验中是有效的。 (C) 2009 年由 Elsevier Masson SAS 代表法国风湿病学会出版。
Primary Sjogren's syndrome was long a vexing dilemma, as the underlying pathophysiological mechanisms remained obscure, disease activity was challenging to evaluate, and no specific treatments were known to be effective. However, recent years have witnessed major advances in these three areas. Convincing evidence has been obtained that innate immunity, most notably mediated by the interferons, plays a role in the initial B-cell activation. A disease activity score was developed during a consensus conference sponsored by the EULAR. Even more importantly, B-cell depletion constitutes a highly promising therapeutic approach. Thus, rituximab was effective in two controlled clinical trials. (C) 2009 Published by Elsevier Masson SAS on behalf of the Societe Francaise de Rhumatologie.